vs
Side-by-side financial comparison of Foxx Development Holdings Inc. (FOXX) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
Foxx Development Holdings Inc. is the larger business by last-quarter revenue ($16.7M vs $13.3M, roughly 1.3× Laird Superfood, Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -25.6%, a 12.5% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -4.4%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
FOXX vs LSF — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $16.7M | $13.3M |
| Net Profit | $-4.3M | $-1.8M |
| Gross Margin | 13.3% | 34.1% |
| Operating Margin | -13.3% | -13.5% |
| Net Margin | -25.6% | -13.2% |
| Revenue YoY | -4.4% | 15.0% |
| Net Profit YoY | -400.9% | -341.4% |
| EPS (diluted) | $-0.62 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.7M | $13.3M | ||
| Q3 25 | $20.2M | $12.9M | ||
| Q2 25 | $13.9M | $12.0M | ||
| Q1 25 | $11.4M | $11.7M | ||
| Q4 24 | $17.5M | $11.6M | ||
| Q3 24 | $23.1M | $11.8M | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | $-4.3M | $-1.8M | ||
| Q3 25 | $-2.9M | $-975.1K | ||
| Q2 25 | $-4.1M | $-362.2K | ||
| Q1 25 | $-4.1M | $-156.2K | ||
| Q4 24 | $1.4M | $-398.4K | ||
| Q3 24 | $-2.3M | $-166.1K | ||
| Q2 24 | — | $-239.1K | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | 13.3% | 34.1% | ||
| Q3 25 | 13.6% | 36.5% | ||
| Q2 25 | 10.9% | 39.9% | ||
| Q1 25 | 5.8% | 41.9% | ||
| Q4 24 | 12.5% | 38.6% | ||
| Q3 24 | 1.7% | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | -13.3% | -13.5% | ||
| Q3 25 | -4.4% | -7.7% | ||
| Q2 25 | -15.0% | -3.3% | ||
| Q1 25 | -31.3% | -1.9% | ||
| Q4 24 | -12.8% | -4.1% | ||
| Q3 24 | -7.8% | -2.3% | ||
| Q2 24 | — | -3.4% | ||
| Q1 24 | — | -11.0% |
| Q4 25 | -25.6% | -13.2% | ||
| Q3 25 | -14.2% | -7.6% | ||
| Q2 25 | -29.4% | -3.0% | ||
| Q1 25 | -35.9% | -1.3% | ||
| Q4 24 | 8.1% | -3.4% | ||
| Q3 24 | -9.8% | -1.4% | ||
| Q2 24 | — | -2.4% | ||
| Q1 24 | — | -10.3% |
| Q4 25 | $-0.62 | — | ||
| Q3 25 | $-0.42 | — | ||
| Q2 25 | $-0.44 | — | ||
| Q1 25 | $-0.58 | — | ||
| Q4 24 | $0.20 | — | ||
| Q3 24 | $-0.65 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8M | $5.1M |
| Total DebtLower is stronger | $84.8K | — |
| Stockholders' EquityBook value | $-11.8M | $11.5M |
| Total Assets | $42.0M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $5.1M | ||
| Q3 25 | $1.5M | $5.1M | ||
| Q2 25 | $1.9M | $3.9M | ||
| Q1 25 | $3.8M | $7.0M | ||
| Q4 24 | $3.9M | $8.3M | ||
| Q3 24 | $9.2M | $7.9M | ||
| Q2 24 | — | $7.6M | ||
| Q1 24 | — | $7.1M |
| Q4 25 | $84.8K | — | ||
| Q3 25 | $90.2K | — | ||
| Q2 25 | $97.2K | — | ||
| Q1 25 | $100.5K | — | ||
| Q4 24 | $105.5K | — | ||
| Q3 24 | $110.3K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-11.8M | $11.5M | ||
| Q3 25 | $-7.9M | $12.8M | ||
| Q2 25 | $-5.4M | $13.4M | ||
| Q1 25 | $-1.6M | $13.3M | ||
| Q4 24 | $2.2M | $13.2M | ||
| Q3 24 | $457.2K | $13.1M | ||
| Q2 24 | — | $12.6M | ||
| Q1 24 | — | $12.7M |
| Q4 25 | $42.0M | $19.2M | ||
| Q3 25 | $49.8M | $18.9M | ||
| Q2 25 | $26.0M | $20.4M | ||
| Q1 25 | $32.9M | $21.5M | ||
| Q4 24 | $31.9M | $19.3M | ||
| Q3 24 | $49.5M | $18.8M | ||
| Q2 24 | — | $18.0M | ||
| Q1 24 | — | $17.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $284.2K | $68.4K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $284.2K | $68.4K | ||
| Q3 25 | $-376.8K | $1.2M | ||
| Q2 25 | $-1.9M | $-2.8M | ||
| Q1 25 | $-178.4K | $-1.3M | ||
| Q4 24 | $-4.2M | $339.2K | ||
| Q3 24 | $-243.5K | $305.8K | ||
| Q2 24 | — | $642.7K | ||
| Q1 24 | — | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-4.3M | — | ||
| Q3 24 | $-278.5K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -24.4% | — | ||
| Q3 24 | -1.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.97× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOXX
Segment breakdown not available.
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |